Skip to main content
. 2024 Mar 4;26:60. doi: 10.1186/s13075-024-03296-8

Table 3.

GRADE certainty of evidence

Outcome Exposure Study numbers GRADE Evidence quality
Risk of bias Inconsistency Indirectness Imprecision Publication bias
SLE Any vaccine 17 0 -1a 0 0 0 Very Low
SLE HPV vaccine 7 0 -1a 0 0 0 Very Low
SLE HBV vaccine 4 0 -1a 0 0 0 Very Low
SLE Influenza vaccine 2 0 0 0 0 0 Low
SLE COVID-19 vaccine 2 0 -1a 0 0 0 Low
SLE Case-control study 7 0 -1a 0 0 0 Very Low
SLE Cohort study 10 0 -1a 0 0 0 Very Low
SLE North America 7 0 -1a 0 0 0 Very Low
SLE Europe 7 0 0 0 0 0 Low
SLE Asia 3 0 -1a 0 0 0 Very Low
SLE Observation time ≥ 180 days 8 0 0 0 0 0 Low
SLE Observation time < 180 days 8 0 -1a 0 0 0 Very Low

SLE: systemic lupus erythematosus, Explanations: a. high heterogeneity